Clinical Trial Update: Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of Adebrelimab with Apatinib and Gemcitabine/Cisplatin as first-line therapy for unresectable biliary tract cancer; rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Adebrelimab (adebrelimab)
• Apatinib (apatinib)
• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Unresectable Biliary Tract Carcinoma | Phase 2 | Status: RECRUITING